Actividad inducida por androsterona y hemisuccinato de androsterona sobre la presión de perfusión y la resistencia vascular
Palabras clave:
androsterona, flutamida, perfusión, resistencia vascular, ratas Wistar.
Resumen
Introducción. Existen pocos datos sobre los efectos de la androsterona y sus derivados a nivel cardiovascular. Además, el mecanismo molecular de estos andrógenos y su sitio de acción celular son poco claros.Objetivo. Evaluar el efecto inducido por la androsterona y el hemisuccinato de androsterona sobre la presión de perfusión y la resistencia vascular.
Materiales y métodos. Los efectos de la androsterona y del derivado de androsterona sobre la presión de perfusión y la resistencia vascular fueron evaluados en un modelo de corazón aislado de rata (Langendorff).
Resultados. Los resultados mostraron que: 1) el hemisuccinato de androsterona [10-9 M] incrementa la presión de perfusión y la resistencia vascular en comparación con la androsterona [10-9 M]; 2) los efectos del derivado de androsterona [10-9 M-10-5 M] sobre la presión de perfusión no fueron inhibidos por indometacina [10-6 M]; 3) la nifedipina [10-6 M] bloquea los efectos ejercidos por el hemisuccinato de androsterona [10-9 M-10-5 M] sobre la presión de perfusión, y 4) el efecto del derivado de androsterona [10-9 M-10-5 M] sobre la presión de perfusión en presencia de flutamida [10-6 M] fue inhibido.
Conclusiones. Los efectos inducidos por androsterona y hemisuccinato de androsterona sobre la presión de perfusión y la resistencia vascular pueden depender de su estructura química. En el caso de la actividad ejercida por el análogo de androsterona, podría involucrar la interacción del esteroide-receptor androgénico e, indirectamente, la activación del canal de calcio y, consecuentemente, inducir variaciones en la presión de perfusión.
Descargas
Los datos de descargas todavía no están disponibles.
Referencias bibliográficas
1. Yusuf S, Reddy S, Ôunpuu S, Anand S. Clinical cardiology: New frontiers. Global burden of cardiovascular diseases. Part I: General considerations, the epidemiologic transition, risk factors and impact of urbanization. Circulation. 2001;104:2746.
2. van den Hoogen P, Feskens E, Nagelkerke N, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. N Engl J Med. 2000;342:1675-6.
3. Roeters van-Lennep J, Westerveld H, Willem D, Vander E. Risk factors for coronary heart disease: implications of gender. Cardiovasc Res. 2002;53:538-49.
4. Appel H, Weicker H. Ultrastructural and morphometric investigations on the effects of training and administration of anabolic steroids on the myocardium of guinea pigs. Int J Sports Med. 1983;4:268-74.
5. Gordon T, Kannel W. Premature mortality from coronary heart disease: the Framingham Study. J Am Med Assoc. 1971;215:1617-25.
6. Kentz M, Lugani K. Morbidity and mortality chartbook on cardiovascular, lung and blood diseases. Bethesda, MD: National Heart, Lung, and Blood Institute; 1992. p. 1-55.
7. Boysen G, Nyboe J. Incidence and risk factors for stroke in Copenhagen, Denmark. Stroke. 1988;19:1345-53.
8. Hippisley-Cox J, Pringle M, Crown N, Meal A, Wynn A. Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. British Med J. 2001;322:832.
9. Rossouw J, Prentice R, Manson J, Wu L, Barad D, Barnabei V. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. J Am Med Assoc. 2007;297:1465-77.
10. Kannel G, Hjortland M, McNamara P. Menopause and risk of cardiovascular disease: the Framingham Study. Ann Intern Med. 1976;85:447-52.
11. Stampfer M, Colditz G, Willett W. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses’ Health Study. N Engl J Med. 1991;325:756-62.
12. Grodstein F, Manson J, Stampfer M. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses’ Health Study: A prospective, observational study. Ann Intern Med. 2001;135:1-8.
13. Cauley J, Gutai J, Kuller L. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol. 1989;129:1120-31.
14. Liu P, Death A. Handelsman D. Androgens and cardiovascular disease. Endocr Rev. 2003;24:313-40.
15. Levy D, Kannell W. Cardiovascular risks: New insights for Framingham. J Am Heart. 1988;116:266-72.
16. Zumoff B, Troxler R, O’Connor J, Rosenfeld R, Kream J, Levin J. Abnormal hormone levels in men with coronary artery disease. Arteriosclerosis. 1982;2:58-67.
17. Carson P, McDonald L, Pickard S, Pilkington T, Davies B. Effects of clofibrate with androsterone (atromid) and without androsterone (atromid-S) on blood platelets and lipids in ischaemic heart disease. Brit Heart J. 1966;28:400-3.
18. Melentyev A. Psyological features of patients with ischaemic heart disease and coronary behavior type “A”. Arteriosclerosis. 2000;151:225-6.
19. Nestler J, Usiskin K, Barlascini C, Welty D, Clore J, Blackard W. Suppression of serum dehydroepiandrosterone sulfate levels by insulin: an evaluation of possible mechanisms. J Clin Endocrinol Metab. 1989;69:1040-6.
20. Ding A, Stallone J. Testosterone-induced relaxation of rat aorta is androgen structure specific and involves K+ channel activation. J Appl Physiol. 2001;91:2742-50.
21. Slowinska-Srzednicka J, Zgliczynski S, Soszynski P, Makowska A, Zgliczynski W, Srzednicki M, et al. Decreased plasma levels of dehydroepiandrosterone sulphate (DHEA-S) in normolipidaemic and hyperlipo-proteinaemic young men with coronary artery disease. J Intern Med. 1991;230:551-3.
22. Gray A, Feldman H, Mckinlay J, Longcope C. Age, disease, and changing sex hormone levels in middle-age men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73:1016-25.
23. Nestler J, Beer N, Jakubowicz D, Colombo C, Beer R. Effects of insulin reduction with benfluorex on serum dehydroepiandrosterone (DHEA), DHEA sulfate, and blood pressure in hypertensive middle-aged and elderly men. J Clin Endocrinol Metab. 1995;80:700-6.
24. Schunkert H, Hense H, Andus T, Riegger G, Straub R. Relation between dehydroepiandrosterone sulfate and blood pressure levels in a population-based sample. Am J Hypertens. 1999;12:1140-3.
25. Kawano H, Yasue H, Kitagawa A, Hirai N, Yoshida T, Soejima H, et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab. 2003;88:3190-5.
26. Ceballos G, Figueroa L, Rubio I, García A, Martínez A, Yañez R. Acute and nongenomic effects of testosterone on isolated and perfused rat heart. J Cardiovasc Pharmacol. 1999;33:691-7.
27. Kontula K, Seppanen P, Duyne P, Bardin C, Janne O. Effect of a nonsteroidal antiandrogen, flutamide, on androgen receptor dynamics and ornithine decarboxylase gene expression in mouse kidney. Endocrinology. 1985;116:226-33.
28. Henry PD. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol. 1980;46:1047-58
29. Yamamoto T, Nozaki-Taguchi N. Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor.Brain Res. 1996;739:104-10.
30. Figueroa-Valverde L, Luna H, Castillo-Henkel C, Muñoz-García O, Morato-Cartagena T, Ceballos-Reyes G. Synthesis and evaluation of the cardiovascular effects of two, membrane impermeant, macromolecular complexes of dextran-testosterone. Steroids. 2002; 67: 611-9.
31. Figueroa-Valverde L, Díaz-Cedillo F, Diaz-Ku E, Camacho-Luis A. Effect induced by hemisuccinate of pregnenolone on perfusion pressure and vascular resistance in isolated rat heart. African J Pharm Pharmacol. 2009;3:234-41.
32. Figueroa-Valverde L, Díaz-Cedillo F, Tolosa L, Maldonado M, Ceballos G. Synthesis of pregnenolone-pregnenolone dimer via ring A-ting a connection. J Mex Chem Soc. 2006;50:42-5.
33. Institute of Laboratory Animal, Resources Commission on Life Sciences, National Research Council. Guide for the care and use of laboratory animals. Seventh edition. Washington, D.C.: National Academies Press; 1996. p. 1-240.
34. Neely J, Liebermeister H, Battersby E, Morgan H. Effect of pressure development on oxygen consumption by isolated rat heart. Am J Physiol. 1967;212:804-14.
35. Hocht C, Opezzo J, Gorzalczany S, Bramuglia G, Tiara C. Una aproximación cinética y dinámica de metildopa en ratas con coartación aórtica mediante microdiálisis. Rev Argent Cardiol. 1999;67:769-73.
36. Mombouli J, Vanhoutte P. Endothelial dysfunction: a novel therapeutic target endothelial dysfunction: From physiology to therapy. J Mol Cell Cardiol. 1999;31:61-74.
37. Schork M, Morinelli A, Masuda A. Testosterone treatment enhances thrombosane A2 mimetic. Induced coronary artery vasoconstriction in guinea pigs. Eur J Clin Invest. 1994: 24(Suppl.1);50-2.
38. Pham T, Robinson R, Danilo P, Rosen M. Effects of gonadal steroids on gender-related differences in transmural dispersion of L-type calcium current. Cardiovasc Res. 2002;53:752-62.
39. Guo Z, Peter W, Benten M, Krücken J, Wunderlich F. Nongenomic testosterone calcium signaling, genotropic actions in androgen receptor-free macrophages. J Biol Chem. 2002;277:29600-7.
40. Reckelhoff J, Zhang H, Srivastava K, Granger J. Gender differences in hypertension in spontaneously hypertensive rats. Role of androgens and androgen receptor. Hypertension. 1999;34:920-3.
41. Er F, Michels G, Brandt M, Khan I, Haase H, Eicks M, et al. Impact of testosterone on cardiac L-type calcium channels and Ca2+ sparks: Acute actions antagonize chronic effects. Cell Calcium. 2007;41:467-77.
42. Wolff E, Ho W, Kwok R. The steroid-receptor complex. Some considerations based on sp2-hybrized systems. J Med Chem. 1964;7:77-89.
2. van den Hoogen P, Feskens E, Nagelkerke N, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. N Engl J Med. 2000;342:1675-6.
3. Roeters van-Lennep J, Westerveld H, Willem D, Vander E. Risk factors for coronary heart disease: implications of gender. Cardiovasc Res. 2002;53:538-49.
4. Appel H, Weicker H. Ultrastructural and morphometric investigations on the effects of training and administration of anabolic steroids on the myocardium of guinea pigs. Int J Sports Med. 1983;4:268-74.
5. Gordon T, Kannel W. Premature mortality from coronary heart disease: the Framingham Study. J Am Med Assoc. 1971;215:1617-25.
6. Kentz M, Lugani K. Morbidity and mortality chartbook on cardiovascular, lung and blood diseases. Bethesda, MD: National Heart, Lung, and Blood Institute; 1992. p. 1-55.
7. Boysen G, Nyboe J. Incidence and risk factors for stroke in Copenhagen, Denmark. Stroke. 1988;19:1345-53.
8. Hippisley-Cox J, Pringle M, Crown N, Meal A, Wynn A. Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. British Med J. 2001;322:832.
9. Rossouw J, Prentice R, Manson J, Wu L, Barad D, Barnabei V. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. J Am Med Assoc. 2007;297:1465-77.
10. Kannel G, Hjortland M, McNamara P. Menopause and risk of cardiovascular disease: the Framingham Study. Ann Intern Med. 1976;85:447-52.
11. Stampfer M, Colditz G, Willett W. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses’ Health Study. N Engl J Med. 1991;325:756-62.
12. Grodstein F, Manson J, Stampfer M. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses’ Health Study: A prospective, observational study. Ann Intern Med. 2001;135:1-8.
13. Cauley J, Gutai J, Kuller L. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol. 1989;129:1120-31.
14. Liu P, Death A. Handelsman D. Androgens and cardiovascular disease. Endocr Rev. 2003;24:313-40.
15. Levy D, Kannell W. Cardiovascular risks: New insights for Framingham. J Am Heart. 1988;116:266-72.
16. Zumoff B, Troxler R, O’Connor J, Rosenfeld R, Kream J, Levin J. Abnormal hormone levels in men with coronary artery disease. Arteriosclerosis. 1982;2:58-67.
17. Carson P, McDonald L, Pickard S, Pilkington T, Davies B. Effects of clofibrate with androsterone (atromid) and without androsterone (atromid-S) on blood platelets and lipids in ischaemic heart disease. Brit Heart J. 1966;28:400-3.
18. Melentyev A. Psyological features of patients with ischaemic heart disease and coronary behavior type “A”. Arteriosclerosis. 2000;151:225-6.
19. Nestler J, Usiskin K, Barlascini C, Welty D, Clore J, Blackard W. Suppression of serum dehydroepiandrosterone sulfate levels by insulin: an evaluation of possible mechanisms. J Clin Endocrinol Metab. 1989;69:1040-6.
20. Ding A, Stallone J. Testosterone-induced relaxation of rat aorta is androgen structure specific and involves K+ channel activation. J Appl Physiol. 2001;91:2742-50.
21. Slowinska-Srzednicka J, Zgliczynski S, Soszynski P, Makowska A, Zgliczynski W, Srzednicki M, et al. Decreased plasma levels of dehydroepiandrosterone sulphate (DHEA-S) in normolipidaemic and hyperlipo-proteinaemic young men with coronary artery disease. J Intern Med. 1991;230:551-3.
22. Gray A, Feldman H, Mckinlay J, Longcope C. Age, disease, and changing sex hormone levels in middle-age men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73:1016-25.
23. Nestler J, Beer N, Jakubowicz D, Colombo C, Beer R. Effects of insulin reduction with benfluorex on serum dehydroepiandrosterone (DHEA), DHEA sulfate, and blood pressure in hypertensive middle-aged and elderly men. J Clin Endocrinol Metab. 1995;80:700-6.
24. Schunkert H, Hense H, Andus T, Riegger G, Straub R. Relation between dehydroepiandrosterone sulfate and blood pressure levels in a population-based sample. Am J Hypertens. 1999;12:1140-3.
25. Kawano H, Yasue H, Kitagawa A, Hirai N, Yoshida T, Soejima H, et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab. 2003;88:3190-5.
26. Ceballos G, Figueroa L, Rubio I, García A, Martínez A, Yañez R. Acute and nongenomic effects of testosterone on isolated and perfused rat heart. J Cardiovasc Pharmacol. 1999;33:691-7.
27. Kontula K, Seppanen P, Duyne P, Bardin C, Janne O. Effect of a nonsteroidal antiandrogen, flutamide, on androgen receptor dynamics and ornithine decarboxylase gene expression in mouse kidney. Endocrinology. 1985;116:226-33.
28. Henry PD. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol. 1980;46:1047-58
29. Yamamoto T, Nozaki-Taguchi N. Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor.Brain Res. 1996;739:104-10.
30. Figueroa-Valverde L, Luna H, Castillo-Henkel C, Muñoz-García O, Morato-Cartagena T, Ceballos-Reyes G. Synthesis and evaluation of the cardiovascular effects of two, membrane impermeant, macromolecular complexes of dextran-testosterone. Steroids. 2002; 67: 611-9.
31. Figueroa-Valverde L, Díaz-Cedillo F, Diaz-Ku E, Camacho-Luis A. Effect induced by hemisuccinate of pregnenolone on perfusion pressure and vascular resistance in isolated rat heart. African J Pharm Pharmacol. 2009;3:234-41.
32. Figueroa-Valverde L, Díaz-Cedillo F, Tolosa L, Maldonado M, Ceballos G. Synthesis of pregnenolone-pregnenolone dimer via ring A-ting a connection. J Mex Chem Soc. 2006;50:42-5.
33. Institute of Laboratory Animal, Resources Commission on Life Sciences, National Research Council. Guide for the care and use of laboratory animals. Seventh edition. Washington, D.C.: National Academies Press; 1996. p. 1-240.
34. Neely J, Liebermeister H, Battersby E, Morgan H. Effect of pressure development on oxygen consumption by isolated rat heart. Am J Physiol. 1967;212:804-14.
35. Hocht C, Opezzo J, Gorzalczany S, Bramuglia G, Tiara C. Una aproximación cinética y dinámica de metildopa en ratas con coartación aórtica mediante microdiálisis. Rev Argent Cardiol. 1999;67:769-73.
36. Mombouli J, Vanhoutte P. Endothelial dysfunction: a novel therapeutic target endothelial dysfunction: From physiology to therapy. J Mol Cell Cardiol. 1999;31:61-74.
37. Schork M, Morinelli A, Masuda A. Testosterone treatment enhances thrombosane A2 mimetic. Induced coronary artery vasoconstriction in guinea pigs. Eur J Clin Invest. 1994: 24(Suppl.1);50-2.
38. Pham T, Robinson R, Danilo P, Rosen M. Effects of gonadal steroids on gender-related differences in transmural dispersion of L-type calcium current. Cardiovasc Res. 2002;53:752-62.
39. Guo Z, Peter W, Benten M, Krücken J, Wunderlich F. Nongenomic testosterone calcium signaling, genotropic actions in androgen receptor-free macrophages. J Biol Chem. 2002;277:29600-7.
40. Reckelhoff J, Zhang H, Srivastava K, Granger J. Gender differences in hypertension in spontaneously hypertensive rats. Role of androgens and androgen receptor. Hypertension. 1999;34:920-3.
41. Er F, Michels G, Brandt M, Khan I, Haase H, Eicks M, et al. Impact of testosterone on cardiac L-type calcium channels and Ca2+ sparks: Acute actions antagonize chronic effects. Cell Calcium. 2007;41:467-77.
42. Wolff E, Ho W, Kwok R. The steroid-receptor complex. Some considerations based on sp2-hybrized systems. J Med Chem. 1964;7:77-89.
Cómo citar
1.
Figueroa L, Díaz F, Camacho A, Díaz E, Marvin R. Actividad inducida por androsterona y hemisuccinato de androsterona sobre la presión de perfusión y la resistencia vascular. biomedica [Internet]. 1 de diciembre de 2009 [citado 16 de abril de 2024];29(4):625-34. Disponible en: https://revistabiomedica.org/index.php/biomedica/article/view/140
Publicado
2009-12-01
Número
Sección
Artículos originales
| Estadísticas de artículo | |
|---|---|
| Vistas de resúmenes | |
| Vistas de PDF | |
| Descargas de PDF | |
| Vistas de HTML | |
| Otras vistas | |
